Epigenetics Market size is estimated to reach ~USD 5 Billion by the end of 2035 by growing at a CAGR of ~17% over the forecast period, i.e., 2023 – 2035. In addition to this, in the year 2022, the market size of epigenetics was ~USD 2 Billion. The growth of the market can be attributed to the rising incidence of cardiovascular diseases (CVDs) and the growing demand for personalized medicines. The World Health Organization estimates that 17.9 million people die each year from cardiovascular diseases (CVDs). According to the Centers for Disease Control and Prevention (CDC), people in the United States die of cardiovascular disease every 34 seconds. There were 697,000 deaths attributed to heart disease in the United States in 2020. As CVDs become more common, there is an increasing need for precision medicine solutions to identify and treat risk factors early on. Epigenetic testing is becoming increasingly popular as a tool to detect and identify at-risk individuals and to develop treatments tailored to the individual's unique genetic characteristics.
In addition to these, factors that are believed to fuel the market growth of epigenetics include increasing public awareness regarding the benefits of epigenetic tests, and a rise in the incidence of genetic conditions. Every year, approximately 1 in 200,000 people in the United States are diagnosed with syndrome A. There were an estimated 15,000 cases of syndrome B diagnosed worldwide in 2020. An increase in the number of people with genetic conditions has led to an increased demand for epigenetics services, such as DNA sequencing, epigenetic therapy, and genetic testing. These services allow for the diagnosis and treatment of genetic disorders. Furthermore, the emergence of new epigenetics technologies, such as ChIP-Seq, RNA-Seq, and ATAC-Seq, is also contributing to the growth of the market.
Base Year |
2022 |
Forecast Year |
2023-2035 |
CAGR |
~17% |
Base Year Market Size (2022) |
~ USD 2 Billion |
Forecast Year Market Size (2035) |
~ USD 5 Billion |
Regional Scope |
|
Growth Drivers
Challenges
The global epigenetics industry is segmented and analyzed for demand and supply by product into kits and reagents, enzymes, and instruments. Out of these, the kits and reagents segment is estimated to gain the largest market share of about ~43% in the year 2035. The growth of the segment can be attributed to the increased demand for kits and reagents owing to the growing demand for precision medicine, the rising number of research activities in the field of epigenetics, and the increasing prevalence of cancer among other diseases. It is estimated that more than 74,000 genetic testing products and 300 personalized medicines are available for people suffering from different types of cancers, genetic diseases, chronic conditions, and infectious diseases. Additionally, continuous technological advancements and increasing investments in the biotechnology sector are anticipated to further drive the growth of the segment.
The global epigenetics market is segmented and analyzed for demand and supply by technology into methylation, acetylation, phosphorylation, and others. Out of these, the methylation segment is estimated to gain a significant market share of about ~37% in the year 2035. The growth of the segment can be attributed to the rising demand for DNA methylation technology in the pharmaceutical and biotechnology industries, as it helps to study the effects of environmental and dietary factors on gene expression. Additionally, the development of next-generation sequencing technologies has enabled researchers to identify methylation sites on a large scale, thereby driving the growth of the segment. The advent of next-generation sequencing technologies has allowed for the rapid and accurate identification of methylation sites, which has enabled researchers to better understand the effects of environmental and dietary factors on gene expression.
Our in-depth analysis of the global epigenetics market includes the following segments:
By Product |
|
By Application |
|
By End User |
|
By Technology |
|
The market share of epigenetics in North America, amongst the market in all the other regions, is projected to be the largest with a share of about ~35% by the end of 2035. The growth of the market can be attributed primarily to the rapid development of healthcare infrastructure and the increasing prevalence of cancer in the population. According to the American Cancer Society, as of 2022, the number of new cancer cases in the United States was estimated to be 1.9 million, and the number of cancer deaths was calculated to be 609,360. The rising number of cancer cases has increased the demand for advanced treatment options, such as epigenetics, which can help identify and target individual cancer cells. Moreover, a significant amount of money is being invested in understanding the molecular basis of cancer in the United States, with the aim of developing cancer therapeutics. Additionally, the availability of sophisticated tools and technologies, the growing focus of government initiatives on the development of life sciences, and the presence of a large number of major players in the region are some of the other factors contributing to the growth of the epigenetics market in North America.
The Asia Pacific epigenetics market is estimated to be the second largest, registering a share of about ~27% by the end of 2035. The growth of the market can be attributed majorly to the increasing prevalence of lifestyle diseases and growing awareness among the population about epigenetics. With the rise in lifestyle diseases such as diabetes and obesity, there is an increased demand for personalized treatments that are tailored to each person's genetic makeup. This has led to an increased focus on epigenetics, which studies how gene expression can be modified without changing the underlying genetic code. Additionally, the rise in R&D investments, supportive government initiatives and policies, and the development of innovative products in the market are some of the other factors that are propelling the growth of the Asia Pacific epigenetics market.
Further, the epigenetics market in Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2035. The growth of the market can be attributed majorly to technological advancements, such as the development of innovative products and services, and the increasing number of collaborations and partnerships between the industry players in the region. Recent technological advancements in the field of epigenetics, such as the development of new tools and techniques to study gene expression, have enabled the rapid development of a range of products and services. This has enabled the European epigenetics market to be competitive in a world market and to develop innovative products and services to meet customer needs. Additionally, the growing awareness about epigenetics among healthcare professionals and end-users is also expected to contribute to the growth of the market in Europe.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: Increasing prevalence of lifestyle-related chronic diseases such as cancer, diabetes, and cardiovascular diseases, and increasing research activities in the field of epigenetics are the major factors driving the market growth.
Ans: The market size of epigenetics is anticipated to attain a CAGR of ~17% over the forecast period, i.e., 2023 – 2035.
Ans: High cost associated with epigenetics services and the lack of skilled professionals to interpret the results of epigenetics tests are estimated to be the growth hindering factors for the market expansion.
Ans: The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Ans: The major players in the market are Abcam PLC, Diagenode Inc., Merck KGaA, Element Biosciences, Inc., PacBio, Active Motiff, Illumina Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., EpiGentek Group Inc., and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by product, application, end user, technology and by region.
Ans: The kits and reagents segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Submit Your Request For Proposal (RFP)